Home MarketSun Pharma Advanced Research Company Ltd.

Sun Pharma Advanced Research Company Ltd. Stock Info: As on 2018-05-24 15:56:20

Nse

356.05

-3.70(-1.03%)
Change%
52 Week Range
272.00
30.00
532.00
12.00
Open359.05
Day's Range287.80 - 431.70
Value Traded (in ₹ Cr.) 4.43

Bse

355.75

-2.65(-0.74%)
Change %
52 Week Range
273.00
29.00
532.40
12.00
Open361.00
Day's Range286.72 - 430.08
Value Traded (in ₹ Cr.) 0.90

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 169,296,119.00 67.47%
Mutual Funds/UTI 4,912,391.00 1.96%
FII 17,515,455.00 6.98%
Employee 0.00 0.00%
Public 35,301,284.00 14.07%
Government 0.00 0.00%
Others 23,785,467.00 9.48%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 43.20
Basic EPS (Rs.) -4.87
Cash EPS -4.54
BVPerShare Excl 6.47
Operating Revenue 7.33
PBDITPerShare -4.46
Dividend 0.00
NPPerShare -4.87
Current Ratio 1.47
Quick Ratio 1.47
PriceToBV 48.98
Earnings -0.01
PBDIT Margin -60.87
PBT Margin -66.43
NP Margin -66.43
Return On Assets -43.88
Retention Ratios 0.00
Parameter Mar-17 (₹ Cr.) Yoy%change
Total Income 194.65
Total Expenses 314.92
EBITDA -110.21
PBT -120.27
PAT -120.27
Net Income -120.27
More
Parameter Mar-18 (₹ Cr.) 6M % change
Total Income 42.17
Total Expenses 146.71
EBITDA -108.58
PBT -55.59
PAT -55.59
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-17 (₹ Cr.) Yoy%change
Total share capital 24.69
Net worth 159.65
Investments 9.55
Total Liability 274.04
Total debt 2.59
Net block 70.63
Total Assets 274.04
Parameter Mar-17 (₹ Cr.) 6M % change
Total share capital 23.67
Net worth 29.90
Investments 0.00
Total Liability 162.66
Total debt 55.21
Net block 70.83
Total Assets 162.66
Company Curr Price Prev. Close Change% W's Low/High

Adani Ports & Special Economic Zone Ltd.

371.25 374.25 -0.8
373.5405.5

Banaras Beads Ltd.

53.25 54.45 -2.2
5257

Binani Industries Ltd.

87.85 88.3 -0.51
87.196

Delta Corp Ltd.

231.3 227.9 1.49
224.6271

Dredging Corporation Of India Ltd.

556.85 558.6 -0.31
551604.9

Future Consumer Ltd.

53.9 54.5 -1.1
52.759.7

Gateway Distriparks Ltd.

165.95 167.7 -1.04
164177.55
Company Curr Price Prev. Close Change% W's Low/High

Adani Ports & Special Economic Zone Ltd.

372 373.5 -0.4
372.75418

Alpha Hi-Tech Fuel Ltd.

0.87 0.91 -4.39
0.870.87

Anil Ltd.

28.9 30.4 -4.93
28.928.9

Bagalkot Udyog Ltd.

23.9 25.15 -4.97
23.923.9

Banaras Beads Ltd.

53.45 55.2 -3.17
50.258.75

Binani Industries Ltd.

87.6 88.2 -0.68
8898.8

Brahmanand Himghar Ltd.

4.08 4.29 -4.9
4.084.08
More
Parameter Mar-17(in ₹ Cr.)
Cash from operating activities 128.04
Cash from investing activities 4.71
Cash from financing activities -192.35
Net change in cash -59.58

Stock Held By Mutual Fund Schemes

Corporate Details

About Management

2007 - Sun Pharma Advanced Research Co.Ltd was formed in the year 2007, with separation of India's leading specialty pharma company, Sun Pharmaceutical Industries Ltd, and its active projects in drug discovery and innovation into a new company. The parent company, Sun Pharma Industries Ltd continues to invest independently in generic research. - Sun Pharma Advanced Research Company Ltd (SPARCL) had allotted 3,39,441 equity shares of Re 1 each to the bond-holders of Sun Pharma Industries Ltd (SPIL) on conversion of 5,500 foreign currency convertible bonds upon conversion. - Balance Sheet along with the Profit and Loss Account for the year ended March 31, 2007 adopted and the Reports of Directors & Auditors thereon. - Mr. Dilip S Shanghvi and Mr. Sudhir V Valia, re appointed as the Directors of the Company. - According to the clause 10.2 of the scheme of arrangement of demerger, sanctioned by the High Court of Gujarat through its order dated March 01, 2007, issued on March 28, 2007 and as per supplementary Trust Deed dated may 18, 2007, the FCCB's holders of Sun Pharma Industries Ltd, are entitled for one equity share of Re 1 each of the company for every equity share of Rs.5 each of SPIL. 2011 - "Sun Pharma announces USFDA approval for DOCEFREZ (docetaxel) for Injection". 2012 -SPARC - Starhaler Device finalist at Medical Design Excellence Awards -Sun Pharma Advanced Research Company Ltd Issues Rights in the Ratio of 1:7 2013 -SPARC to provide update on NCE & NDDS programs 2014 -SPARC Announces India Approval for Paclitaxel Injection Concentrate for Nanodispersion (PICN) 2017 - SPARC has received a Complete Response Letter (CRL) from the USFDA for its New Drug Application (NDA) for Elepsia XRTM, Levetiracetam extended-release tablets 1000 mg and 1500 mg.

Registered Office

17-B, Mahal Industrial Estate, Mahakali Caves Road, Andheri (East)

,,,      ,

Registrar Details

Link Intime India Pvt. Ltd.